{"product_id":"alkermes-marketing-mix","title":"Alkermes Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlkermes blends specialized CNS therapies with targeted pricing, selective distribution through specialty pharmacies, and focused promotion to clinicians and payers—this snapshot hints at strategic depth but only scratches the surface; get the full 4P’s Marketing Mix Analysis for an editable, data-driven report that saves research time and fuels presentations, benchmarking, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLYBALVI for Schizophrenia and Bipolar I\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLYBALVI (olanzapine + samidorphan) anchors Alkermes’ CNS portfolio by reducing olanzapine-linked weight gain, positioning it as a metabolic-friendly oral antipsychotic; by end-2025 it reached estimated $360M annual U.S. net sales and grew market share among oral atypicals to ~6%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARISTADA Long-Acting Injectable Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eARISTADA, an extended-release injectable suspension of aripiprazole lauroxil for schizophrenia, offers dosing options from 441 mg to 1064 mg with intervals from monthly to every two months, allowing clinicians to tailor therapy to patient needs.\u003c\/p\u003e\n\u003cp\u003eThis dosing flexibility differentiates Alkermes in the LAI (long-acting injectable) market, supporting improved adherence; real-world studies to 2024 show LAIs reduce relapse risk by ~30–40% versus oral antipsychotics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVIVITROL for Opioid and Alcohol Dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVIVITROL is a monthly naltrexone injectable that blocks opioid receptors, offering a non-addictive option for opioid and alcohol use disorders; sales were about $388M in 2023 and remained a core Alkermes asset through 2024.\u003c\/p\u003e\n\u003cp\u003eIt is widely used in specialty treatment centers and correctional health settings, supporting continuity of care where adherence is critical; studies show monthly dosing improves retention vs daily oral naltrexone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrexin-2 Receptor Agonist Pipeline ALKS 2680\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy late 2025, ALKS 2680, an orexin-2 receptor agonist, is a high-potential developmental asset targeting narcolepsy and other hypersomnolence disorders, with Phase 2\/3 readouts expected to de-risk commercial prospects.\u003c\/p\u003e\n\u003cp\u003eAlkermes leverages its CNS expertise to address orexin deficiency; successful trials to date showed clinically meaningful wakefulness gains and a favorable safety signal, positioning ALKS 2680 as a neurology growth driver.\u003c\/p\u003e\n\u003cp\u003eAnalysts model peak-year U.S. sales of $600–900M by 2032 assuming approval and 25–35% market penetration in treated narcolepsy patients; trial milestones materially impact valuation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: narcolepsy, hypersomnolence\u003c\/li\u003e\n\u003cli\u003eMechanism: orexin-2 receptor agonist\u003c\/li\u003e\n\u003cli\u003eStage: late 2025 — Phase 2\/3 development\u003c\/li\u003e\n\u003cli\u003eProjected peak U.S. sales: $600–900M by 2032\u003c\/li\u003e\n\u003cli\u003eKey risk: pivotal trial success and regulatory approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary LinkeRx and NanoCrystal Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlkermes uses Proprietary LinkeRx and NanoCrystal tech to create long-acting CNS formulations, cutting daily dosing and improving adherence; in 2025 the company reported \u0026gt;$850m in platform-enabled product sales and 3 partnered approvals since 2020.\u003c\/p\u003e\n\u003cp\u003eThese platforms speed new molecular entity work and enhance pharmacokinetics—examples include multi-week injectables that extend half-lives 4–10x versus oral analogs, lowering clinic visits and steadying plasma levels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform-driven sales \u0026gt;$850m (2025)\u003c\/li\u003e\n\u003cli\u003e3 partnered approvals since 2020\u003c\/li\u003e\n\u003cli\u003e4–10x half-life extension typical\u003c\/li\u003e\n\u003cli\u003eFewer daily doses, higher adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes portfolio: LYBALVI, ARISTADA, VIVITROL drive growth; ALKS 2680 upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes’ product mix centers on LYBALVI (2025 U.S. net sales ~$360M; ~6% oral atypical share), ARISTADA (monthly–q8w LAI dosing 441–1064 mg), VIVITROL (2023 sales ~$388M; core in specialty\/corrections), and ALKS 2680 (late-2025 Phase 2\/3; modeled peak U.S. sales $600–900M by 2032).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2023–2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLYBALVI\u003c\/td\u003e\n\u003ctd\u003e2025 U.S. net sales \/ market share\u003c\/td\u003e\n\u003ctd\u003e$360M \/ ~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARISTADA\u003c\/td\u003e\n\u003ctd\u003eDosing options\u003c\/td\u003e\n\u003ctd\u003e441–1064 mg; monthly–q8w\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIVITROL\u003c\/td\u003e\n\u003ctd\u003e2023 sales \/ channels\u003c\/td\u003e\n\u003ctd\u003e$388M; specialty \u0026amp; corrections\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALKS 2680\u003c\/td\u003e\n\u003ctd\u003eStage \/ peak sales model\u003c\/td\u003e\n\u003ctd\u003eLate-2025 P2\/3; $600–900M by 2032\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific deep dive into Alkermes’ Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground analysis for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Alkermes' 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotion channels, and placement tactics for rapid decision-making and cross-functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Wholesale and Distribution Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes ships primarily through major wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—covering over 90% of U.S. pharmacy distribution channels; in 2024 these partners helped Fulfillment rates exceed 98% for marketed products. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes uses specialty pharmacy networks for complex CNS meds like ARISTADA and LYBALVI; these pharmacies handled an estimated 75% of specialty fills in 2024, improving adherence and monitoring.\u003c\/p\u003e\n\u003cp\u003eThey offer benefit verification, prior authorization support, and counseling, reducing initiation delays—median time-to-first-dose fell from 18 to 8 days in a 2023 cohort.\u003c\/p\u003e\n\u003cp\u003eThis targeted channel helps overcome access barriers and enhances patient experience, cutting specialty-related discontinuation by ~20% in payer programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Government Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa significant portion of vivitrol distribution goes through hospitals residential treatment centers and correctional facilities in institutional sales accounted for about alkermes volumes per company filings. keeps a dedicated team to manage contracts inventory training so doses reach high-need settings. this public-sector presence helps underserved populations supports community health programs medicaid-funded initiatives.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Manufacturing and Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlkermes runs a major manufacturing and R\u0026amp;D site in Athlone, Ireland, which in 2024 handled roughly 40–50% of the company’s global biologics and drug-delivery manufacturing volume and supported key pipeline candidates using proprietary delivery platforms.\u003c\/p\u003e\n\u003cp\u003eThe Ireland hub helps Alkermes manage a global supply chain across North America, Europe, and Asia, meet EMA and FDA standards, and reduce lead times; in 2024 the site contributed to a ~15% reduction in average product release timelines versus 2022.\u003c\/p\u003e\n\u003cp\u003eThe Athlone facility is central to producing products based on Alkermes’ proprietary drug delivery technologies, supporting both commercial launches and late-stage clinical manufacturing with capacity expansion investments announced in 2023–2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAthlone: ~40–50% of manufacturing volume (2024)\u003c\/li\u003e\n\u003cli\u003eSupply-chain efficiency: ~15% faster releases vs 2022\u003c\/li\u003e\n\u003cli\u003eRegulatory: EMA and FDA-compliant site\u003c\/li\u003e\n\u003cli\u003eInvestment: capacity expansions announced 2023–2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician-Administered Treatment Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlkermes targets physician-administered sites for ARISTADA (antipsychotic) and VIVITROL (opioid dependence), ensuring clinic and outpatient availability; in 2024 these channels accounted for a majority of injectable dispenses in the US specialty market (estimated 60–70%).\u003c\/p\u003e\n\u003cp\u003eThe company supplies training, administration guides, and billing support, and funds cold-chain equipment where needed to reduce wastage and delays; reported site onboarding time fell to ~10 days in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60–70% of US injectable specialty dispenses via clinics (2024 est.)\u003c\/li\u003e\n\u003cli\u003eSite onboarding ~10 days (2024)\u003c\/li\u003e\n\u003cli\u003eCold-chain support reduces spoilage and missed doses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlkermes: \u0026gt;90% wholesaler reach, 75% specialty fills, faster manufacturing \u0026amp; 10-day onboarding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlkermes distributes via major wholesalers (AmerisourceBergen, Cardinal, McKesson) covering \u0026gt;90% US pharmacies; specialty pharmacies handled ~75% specialty fills in 2024, institutional channels (hospitals, correctional) were ~35% of VIVITROL, Athlone made 40–50% of manufacturing (2024) and cut release times ~15% vs 2022; clinic injectables were 60–70% with site onboarding ~10 days.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e~75% fills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIVITROL institutional\u003c\/td\u003e\n\u003ctd\u003e~35% volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAthlone manufacturing\u003c\/td\u003e\n\u003ctd\u003e40–50% volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelease time improvement\u003c\/td\u003e\n\u003ctd\u003e~15% vs 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic injectables\u003c\/td\u003e\n\u003ctd\u003e60–70% dispenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite onboarding\u003c\/td\u003e\n\u003ctd\u003e~10 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAlkermes 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Alkermes 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750241808761,"sku":"alkermes-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alkermes-marketing-mix.png?v=1772223474","url":"https:\/\/matrixbcg.com\/products\/alkermes-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}